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Background: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection.
With this approach, local control ranges between 50% and 70%, depending on resection status. A series or smaller
studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival,
which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and
radiation doses of 60 Gy or higher have been shown to be necessary for tumor control.
Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose
deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in
comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be
calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed.
First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients
with high-risk meningiomas has shown safety, and treatment results are promising.
Methods/design: The Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor
in conjunction with photon radiotherapy in patients with atypical menigiomas after incomplete resection or
biopsy.
Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity.
Discussion: Based on published data on the treatment of atypical meningiomas with carbon ions at GSI, the
present study will evaluate this treatment concept in a larger patient population and will compare outcome to
current standard photon treatment.
Trial registration: NCT01166321.
Background
Meningiomas are the second most common primary
brain tumor and represent approximately 15-26% of all
intracranial neoplasms [1]. Approximately 5-10% of
meningiomas are of non-benign histology (atypical or
anaplastic) and are associated with less favourable out-
come; they are characterized by locally aggressive
growth and early recurrence or tumor progression after
surgery [2]. Therefore, neurosurgical resection alone
does not confer to high long-term local control and
overall survival rates [3]. Moreover, extent of tumor
resection has shown to be a significant prognostic fac-
tor. The resection level is commonly assessed after neu-
rosurgical resection by the surgeon after verification
with a postoperative MRI and is classified according to
Simpson guidelines (see table 1).
Patients after non-radical resection (Simpson Grade 4
and 5) show significantly worse outcome than patients
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any medium, provided the original work is properly cited.after radical neurosurgical resection [4]: In patients with
non-bening meningiomas treated with surgery alone,
local recurrence rates are 50% for subtotally excised,
and 90% for completely resected patients at 3 years as
reported in a large multi-center overview. Local recur-
rence has a major negative impact on survival.
Although meningiomas are classified as relatively
radioresistant tumors, radiation therapy is the most effec-
tive adjuvant treatment available [5-8]. For non-benign
meningiomas, a number of small and non- controlled
series have reported superior outcome after postoperative
radiotherapy as compared to surgery alone [6,9-13].
Novel radiotherapeutic modalities such as protons or
carbon ion radiotherapy offer a promising treatment
alternative. Radiation therapy using charged particles is
characterized by distinct physical and biological charac-
teristics. Charged particles provide the physical advantage
of an inverted dose profile which enables steep dose gra-
dients. Therefore, reduction of dose to normal tissue, and
especially to organs at risk, can be achieved. Heavy
charged particles, such as carbon ions, additionally offer
an increased RBE. Thus, with particle therapy, dose esca-
lation required for long-term control of atypical or malig-
nant meningiomas is feasible while adhering to normal
tissue tolerance constraints. New beam qualilties, such as
carbon ion radiation therapy, offer a promising treatment
alternative in malignant meningiomas. Carbon ion radio-
therapy offers the physical characteristics as do protons,
however, are characterized by a comparably higher RBE.
For aggressive and radioresistant tumors auch as glioblas-
toma cell lines, RBE values between 2 and 5 have been
reported depending on cell line and endpoint [14,15].
Clinically, it has been shown that carbon ion radiation
therapy leads to significantly increased control rates in
treatment-resistant tumors [16-18].
Carbon ion radiotherapy was available by the Depart-
ment of Radiation Oncology at GSI in Darmstadt since
1997. Superior treatment results for a number of tumor
entities, such as chordomas and chondrosarcomas of the
skull base, as well as ACC have been shown, and carbon
ion radiotherapy is currently performed in the clinical
routine for these patients [17,18]. Safety of carbon ion
radiotherapy with respect to critical organs at risk, such
as the brain, brainstem or spinal chord, have been shown
in these studies. At the HIT center, treatment of over
1300 patients per year with Proton and Carbon ion RT is
possible. Worldwide, particle therapy is available in the
clinical routine in a few of centers until now.
Over recent years, a number of centers have implemen-
ted proton radiotherapy for patients with meningiomas,
mainly with benign histology. Results are summarized in
table 2.
Outcome after proton as well as advanced photon radio-
therapy are comparable for the treatment of benign menin-
giomas, with high local control rates and low rates of
treatment-related morbidity. However, for benign menin-
giomas, total doses of 50 to 60 Gy are required for long-
term tumor control. For anaplastic and atypical meningio-
mas, on the other hand, doses of 60 Gy are known to be
not sufficient for long-term tumor control, and possibilities
of dose-escalation play an important role for the improve-
ment of outcome. Smaller studies could show that total
doses exceeding 60Gy are required for long-term tumor
control [13,19]. Therefore, until now, distinctly worse clini-
cal results are still observed observed in WHO Grade II
and III meningiomas. Atyical and anaplastic meningiomas
remain a difficult to treat patient population with high
rates of local tumor recurrences, even after aggressive sur-
gery and adjuvant radiation therapy.
Preliminary results obtained after carbon ion radiother-
apy within a Phase I/II trial performed at GSI could show
safety and feasibility in patient with high-risk meningiomas
treated with a carbon ion boost to the macroscopic tumor
in combination with precision photon radiotherapy deliv-
ered as IMRT or FSRT [20]. These patients had been trea-
ted in our institution within a dose of 50.4 Gy with
photons delivered by FSRT or IMRT, and a carbon ion
boost to the macroscopic tumor with a total dose of 18Gy
E in single doses of 3 Gy E [20]. No severe acute or long-
term toxicity could be observed, and treatment outcome
with with overall survival rates of 75% and 63% at 5 and
7 years is promising, although all patients had macroscopic
tumors at the timepoint of radiotherapy. Therefore, the
concept of a carbon ion boost to patients with atypical
meningiomas with a macroscopic tumor lesion after neu-
rosurgical resection is a promising treatment alternative.
In the present MARCIE trial, impact of a carbon ion
boost using intensity modulated rasterscanning delivered
in combination with precision photon radiotherapy will
be evaluated in a Phase II design in patients with atypi-
cal meningiomas.
Methods and Design
The purpose of the trial is to evaluate a carbon ion
boost to the macroscopic tumor in combination with
photon radiotherapy in patients atypical meningiomas.
Table 1 Simpson grading for Meningioma
Radical
Stage 1 complete excision, including dura and bone
Stage 2 complete excision + supposed reliable coagulation of
dural attachment.
Non-radical
Stage 3 complete excision but insufficient dural coagulation or
bone excision (non visible on MR, according to surgeon’s
opinion)
Stage 4 incomplete excision, macroscopic rest visible (on MRI)
Stage 5 biopsy only (visible on MRI)
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Page 2 of 8The aim of the study is to compare progression-free
survival as a primary endpoint, and overall survival free
survival, toxicity and safety as secondary endpoints.
The primary objective is progression-free survival rate
during the follow-up phase of at least 3 years. The sec-
ondary objectives of the study are overall survival, toxi-
city and safety.
The trial will be performed as a single-center one-
armed Phase II study.
Patients fulfilling the inclusion criteria will be included.
Treatment Schedule
Carbon Ion Radiation Therapy as a Boost to the
macroscopic tumor
Total Dose 18 Gy E, 6 fractions, 3 Gy E single dose
The trial workflow is shown in Figure 1.
Study objectives and endpoints
The primary endpoint is progression-free survival at 3
years, therefore patients are followed within the trial
protocol for a minimum 3 years after completion of
study treatment. For the LPI (last patient in), the final
study visit will be 3 years after study treatment to asses
the primary endpoint. All other patients will be followed
on a regular basis as stated below until death or until
3 years after LPI.
After RT, patients are scheduled for follow-up visits
every 3 months or as needed clinically including contrast-
enhanced MRI as well as thorough clinical-neurological
assessment.
The last patient included into the study will be fol-
lowed 3 years after treatment. This is considered the
final study visit. All other patients will be followed regu-
larly as described in detail until death or until 3 years
after LPI.
The overall duration of the trial is expected to be
approximately 72 months. Recruitment of the patients is
planned over a time period of 36 months, minimum
duration of the follow-up phase will be 36 months.
Patient selection
40 patients should be enrolled in this clinical study ful-
filling the following inclusion criteria.
Inclusion criteria
Patients meeting all of the following criteria will be con-
sidered for admission to the trial:
- histologically confirmed atypical meningioma
- macroscopic tumor after biopsy or subtotal resec-
tion - Simpson Grade 4 or 5
- prior photon radiotherapy to the CTVPhoton of
48-52 Gy
- beginning of study treatment no later than
12 weeks after surgery
- age ≥ 18 years of age
- Karnofsky Performance Score ≥60
Table 2 Results of Proton and Carbon Ion Therapy for Patients with Meningiomas










1990 13 Protons, 59,4 Gy E 100% 100%
Gudjonsson et al. Uppsala,
Sweden
1999 19 Protons, 24 Gy E, 4 fractions - 100% at 3 years
Wenkel et al. MGH,
Boston MA,
USA
2000 46 Protons and Photons, 59.0 Gy E 95% and
77% at 5 and
10 years
100% and 88% at 5 and 10 years
Hug et al. MGH,
Boston MA,
USA
2000 16 Protons and Photons, 62 Gy E for
atypical meningiomas, 58 Gy E for
malignant meningiomas
- 19% at 8 years for atypical
meningiomas, 17% at 8 years for
malignant meningiomas
Vernimmen et al. Tygerberg,
South
Africa
2001 27 Protons, 54 Gy E - 61.6 Gy E, 16 - 27
fractions
- 88%
Noël et al. CPO, Orsay,
France
2002 17 Protons and Photons, 61 Gy E 88.9% at 4
years
87.5% at 4 years
Weber et al. PSI,
Switzerland
2004 16 Protons, 52.2-64 Gy E 92.7% at 3
years
91.7% at 3 years
Noël et al. CPO, Orsay,
France
2005 51 Protons and Photons, 60.6 Gy E 100% at 4
years
98% at 4 years
Combs et al. Heidelberg,
Germany
2010 10 Photons, Carbon Ion Boost 75% and
63% at 5 and
7 years
86% and 72% at 5 and 7 years
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Page 3 of 8- For women with childbearing potential, adequate
contraception.
- Ability of subject to understand character and indi-
vidual consequences of the clinical trial
- Written informed consent (must be available
before enrolment in the trial)
Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
- refusal of the patients to take part in the study
- previous radiotherapy of the brain
- time interval of >12 weeks after primary diagnosis
(neurosurgical intervention) and beginning of study
treatment
- optic nerve sheath meningioma (ONSM)
- Patients who have not yet recovered from acute
toxicities of prior therapies
- Known carcinoma <5 years ago (excluding Carci-
noma in situ of the cervix, basal cell carcinoma,
squamous cell carcinoma of the skin) requiring
immediate treatment interfering with study therapy
- Pregnant or lactating women
- Participation in another clinical study or observa-
tion period of competing trials, respectively.
Figure 1 Flow chart of the MARCIE-Study.
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All Patients will be assigned the same treatment regimen
within this study
Treatment Planning
For radiotherapy, patients will be immobilized using an
individually manufactured head mask. For treatment
planning, contrast-enhanced CT as well as MR-imaging
will be performed for optimal target definition.
Organs at risk such as the brain stem, optic nerves,
chiasm and spinal chord will be contoured. Dose con-
straints of normal tissue will be respected according to
Emami et al. [21].
The carbon ion boost will consist of the GTV includ-
ing the area of contrast enhancement on T1-weighted
MR-imaging; the CTVCarbon for the boost will be
defined adding a safety margin of 5 mm.
Amino-Acid-PET or
68Ga-Dotatoc-PET may be used
in addition to contrast-enhanced MRI for target volume
definition but is not mandatory.
For photon treatment, the CTVPhoton will be defined,
which is applied as 3D-conformal treatment or as
high-precision photon radiotherapy such as FSRT or
IMRT. The CTVPhoton will be contured including the
GTV and sub clinical microscopic tumor (e.g. includ-
ing the pre-operative tumor or post-operative tumor
bed, peritumoral edema, hyperostotic changes if any,
and dural enhancement or thickening as seen in the
CT/MRI at diagnosis) plus a 1 cm safety margin. The
margin may be reduced with respect to anatomical
borders or organs at risk at the discretion of the inves-
tigator. Treatment Planning for Photon Radiotherapy
will be performed using the Planning Systems available
at the Department of Radiation Oncology in Heidel-
berg, Germany (including HELAX-Masterplan/
Nucletron, Virtuos-Konrad/Siemens, or STP/Stryker-
Leibinger).
Carbon ion RT planning is performed using the treat-
ment planning software PT-Planning (Siemens, Erlan-
gen, Germany) including biologic plan optimization.
Biologically effective dose distributions will be calculated
using the a/ß ratio for meningioma as well as for the
endpoint late toxicity to the brain.
No interruptions >4 days between the end of photon
radiotherapy and the carbon ion boost are allowed.
Patient positioning prior to radiotherapy will be evalu-
ated by comparison of x-rays to the DRRs. Set up devia-
tions >3 mm are corrected prior to radiotherapy.
Dose Prescription Carbon Boost
The intensity-controlled rasterscan system will be used
for beam application. Six fractions of a single dose of
3 Gy E up to a total dose of 18 Gy E will be prescribed
to the maximum of the calculated dose distribution for
the target volume. Treatment planning aims at
the coverage of the target volume by the 90%-isodose
line.
Dose specification is based on biologic equivalent dose
because of the high relative biologic effectiveness (RBE)
of carbon ions, which differs throughout the target
volume due to its dependence on various factors. RBE
will be calculated at each voxel throughout the target
volumes and biological optimization will be performed.
The dose prescription used is related to the isoeffective
dose GyE using daily fractions of 2 Gy and a weekly
fractionation of 5 × 2 Gy.
Follow-up
After completion of study treatment no further adjuvant
treatment is scheduled or recommended. Any systemic
treatment or chemotherapy or any other treatment
applied is not part of the clinical trial.
For tumor progression, treatment alternatives will be
evaluated and discussed in the interdisciplinary setting
considering options of neurosurgical resection, systemic
treatment such as chemotherapy, a second course of
radiation therapy, or other.
This study will use the International Common Ter-
minology Criteria for Adverse Events (CTCAE) version
4.0 for toxicity and adverse event reporting. A copy
o rt h eC T C A Ec a nb ea c c e s s e df r o mt h eC T E P
home page (http://ctep.cancer.gov/protocolDevelop-
ment/electronic_applications/ctc.htm).
Safety and toxicity of the study treatment will be eval-
uated by clinical neurological examination as well as
neuro-imaging studies (MRI or CT).
- Progression-free Survival -
Progression-free survival is the primary endpoint of
the study. Progression-free survival will be counted from
the first day of radiotherapy treatment until the date of
the first event of either progression or death due to any
cause. Patients alive without progressive disease at the
time of data analysis will be censored at the time of the
most recent follow-up visit.
Complete remission
Remission of all contrast-enhancing lesions on CT or
MRI without worsening of neurologic status
Partial remission
at least 50% remission of the contrast-enhancing lesions
on CT oder MRI without increase in steroid medication
and without worsening of the neurologic status
Stable disease
Remission of the solid tumor/contrast-enhancing lesion
on CT or MRI of less than 50% or progression of the
solid tumor/contrast-enhancing lesion on CT or MRI of
less than 25%, without increase in steroid medication of
worsening of the neurologic status
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Increase in solid tumor/contrast-enhancing lesion of
25% or more or development of a new lesion
Progression-free survival will be assessed following the
target lesion(s) as defined hereunder
The initial assessment of the disease (including CT and
MRI) must be performed between neurosurgical inter-
vention and the beginning of study treatment. Follow-up
assessments (including MRI or CT) will be performed as
described until disease progression (even after the end
of the study).
Special attention should be given so as to avoid tissue
reaction to radiation treatment to be classified as tumor or
disease progression. Such variations in post-radiotherapy
imaging may continue for months, and may be accompa-
nied by clinical signs and symptoms. In addition, surgical
procedures may cause increased contrast uptake which
should be differentiated from tumor progression. The clin-
ical follow-up must dictate how the initial progression of
the lesion should be labeled. If the course of events shows
that true progression indeed occurred, the date of the first
increase is to be considered as the date of progression.
The principal investigator or the study coordinator may be
contacted for further discussion on a case by case basis.
Radiological progression
The lesion must be measured in the two largest perpen-
dicular diameters; the area should be defined as the pro-
duct of these two diameters.
- Increase of the lesion on MRI or CT scans of more
than 25% as measured by two perpendicular dia-
meters compared to the smallest measurements ever
recorded for the same lesion by the same technique.
- The appearance or new lesions with or without
contrast enhancement.
- Overall Survival -
Overall survival is the primary endpoint of the study. All
patients will be followed until death. The duration of
survival is the time interval between initial diagnosis
(date of the neuropathology report) and the dated of
death due to any cause. Patients not reported dead or
lost to follow-up will be censored at the date of the last
follow-up examination.
Statistical Considerations
The statistical methods applied for this study are subject
to GCP guidelines (Guidelines of the International Con-
ference on Harmonisation (ICH) e.g.
￿ ICH E3: Structure and Contents of Clinical Study
Reports,
￿ ICH E6: Good Clinical Practice (GCP). Consoli-
dated Guideline,
￿ ICH E9: Note for Guidance on Statistical Principles
in Clinical Trials) and will be performed in accordance
with CESAR SOP 8 (Statistical Analysis/Biometry) in
their versions valid at the date of the original study
protocol.
Study Hypothesis
The study is designed to demonstrate that a carbon ion
boost in combination with postoperative photon radio-
therapy can improve the progression-free survival rate
after 3 years (PFS-3yR) by 20%. The benchmark for lar-
gest PFS-3yR which, if true, implies that the efficacy of
study treatment is too low is assumed to be 50% accord-
i n gt ol i t e r a t u r ed a t a( 4 )w i t hac o m p a r a b l ep a t i e n t
population (patients with atypical meningiomas Simpson
grade 4 and 5 and without previous radiotherapy).
Sample Size Calculation
The sample size calculation is based on the analysis of
the primary endpoint PFS-3yR, denoting the rate of pro-
gression-free survival after 3 years of follow-up. The
trial is designed to detect an improvement by 20% in
this primary endpoint. For sample size calculation, the
following hypotheses will be made:
￿ p0 is the largest PFS-3yR which, if true, implies
that the efficacy of the treatment is too low. In the
present trial p0 has been taken as 50%.
￿ p1 is the lowest PFS-3yR which, if true, implies
that the efficacy of the treatment is adequate. In the
present trial p1 has been taken as 70%.
￿ a is the accepted probability of considering ade-
quate efficacy of the treatment with a true PFS-3yR
equal or lower to p0. In the present trial a has been
taken as 5% (actual 0.049).
￿ b is the accepted probability of rejecting adequate
efficacy of the treatment with a true PFS-3yR at least
equal to p1. In the present trial a has been taken as
20% (actual 0.0193).
Using the one-sided binomial test with the given
hypotheses, the study required 37 patients to decide
whether the PFS-3yR is less than or equal to 0.5 or
greater than or equal to 0.7. If the number of progres-
sions or deaths is lower than 13, the hypothesis that
PFS-3yR ≤ 0.5 is rejected with a target error rate of
0.05 and an actual error rate of 0.049. Sample size cal-
culation was done using the software PASS 2008.
Allowing for approximately 10% non-evaluable
patients primarily due to drop out, n = 40 patients will
be recruited.
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tial, PFS-3yR = 0.5 resp. PFS-3yR = 0.7 is equivalent to
a median PFS = 3 years resp. median PFS = 5.8 years.
Analysis Variables
The primary outcome variable is progression-free survi-
val rate at 3 years. Secondary objectives are the assess-
ment of overall survival as well as ‘toxicity’ and ‘safety’.
Analysis Populations
Full Analysis Population
The full analysis set (FAS) according to intention to
treat (ITT) consists of all patients included in the trial
irrespective whether any protocol violation was present
at the time of treatment start or during treatment under
study conditions or whether the patient withdrew con-
sent or was taken off-study any time after treatment
start.
Not included are patients who withdraw informed
consent before start of treatment or about whom it
becomes known that major in/exclusion criteria were
violated which would have excluded them from study
treatment when known at start of treatment.
Per Protocol Population
The per protocol population comprises only patients
meeting eligibility criteria and receiving treatment
according to this protocol.
Safety Population
All patients of the FAS receiving the study treatment at
least once are part of the safety population.
Statistical Methods
Confirmatory Analysis
The primary aim and its corresponding endpoint are
subject to a confirmatory statistical analysis. The pri-
mary aim is to evaluate efficacy of carbon ion boost in
combination with postoperative photon radiotherapy in
patients with atypical meningiomas Simpson grade 4
and 5 on progression-free survival rate after 3 years of
follow-up (PFS-3yR). Formally,
H0: PFS-3yR ≤ 0.5 versus H1: PFS-3yR > 0.5.
PFS-3yR is statistically tested with a one-sided binom-
inal test on the level a = 5%.
Descriptive Analysis
S e c o n d a r ye n d p o i n t sa r ea l lo fe x p l o r a t i v en a t u r ea n d
reported using descriptive analysis methods.
￿ For failure time data (progression-free survival and
overall survival) Kaplan-Meier curves will be dis-
played and median estimates as well as associated
95% confidence intervals will be reported.
￿ Safety/tolerability will be assessed by the type, inci-
dence, severity (graded by the NCT CTCAE Version
4.0), and relatedness of AEs to treatment and by
assessment of all parameters related to safety. Toler-
ability and dosing will be described by numbers of
patients in whom treatment was given as planned,
delayed or permanently stopped.
Data Management
According to the §13 of the German GCP-Regulation all
important trial documents will be archived for at least
10 years after the trial termination.
According to the §28c of the German X-Ray Regula-
tion (RöV) and the §87 of the German Radiation Protec-
tion Regulation (StrlSchV) the informed consent forms
including patients’ consent for trial participation, appli-
cation of irradiation and data transmission to the com-
petent authority will be archived for at least 30 years
after the trial termination.
The Study Center at the Department of Radiation
Oncology Define will be responsible for archiving all
relevant data.
Ethical and Legal Aspects
Good Clinical Practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial by Good Clinical Practice (GCP) and the ethical
principles described in the applicable version of the
Declaration of Helsinki (2008 Version of the Declaration
of Helsinki, adopted at the 59th WMA General Assem-
bly, Seoul, October 2008).
The trial will be carried out by adhereing to local legal
and regulatory requirements.
The study plan has obtained approval by the Institu-
tional Review Board (IRB)/Independent Ethics Commit-
tee (EC) of the Medical Faculty Heidelberg as well as
the Bundesamt für Strahlenschutz (BfS).
Discussion
Treatment optimization for patients with high-grade
meningiomas is a main goal of the radiation oncologist.
It is known, that, for long-term local tumor control,
high doses of radiotherapy are required. Previous studies
have shown beneficial results for particle therapy in
patients with meningiomas, however, most studies have
evaluated proton radiotherapy in low-grade meningioma
patients. Prior studies from our institution have shown
that carbon ion radiotherapy can improve local tumor
control in several tumor types [17,18]. For high grade
meningioma patients, a combined treatment of photon
radiotherapy and a carbon ion boost to the macroscopic
tumor have proven safety and promising efficacy [20].
Therefore, this concept will be evaluated in the first pro-
spective trial on carbon ion radiotherapy for atypical
meningiomas.
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